NAPLEX Quiz: Otc Medications And Supplements

What this quiz covers

This quiz focuses on Otc Medications And Supplements, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Biotin can interfere with certain lab tests; tell the patient to inform the lab/clinician and consider holding biotin before blood draws (correct answer)
2. Biotin must be taken with levothyroxine to improve absorption of thyroid hormone
3. Biotin is contraindicated in hypothyroidism because it causes thyroid failure
4. Biotin is proven to regrow hair in all patients within 2 weeks

Explanation: This question tests counseling on biotin use in thyroid patients. The key patient-specific factor is high-dose biotin interfering with thyroid lab assays, potentially skewing TSH results. Advising to inform lab/clinician and hold biotin before blood draws is most important because it ensures accurate monitoring of hypothyroidism. Requiring co-administration with levothyroxine (B) is incorrect as it does not improve absorption; contraindication claims (C) are misconceptions. Rapid hair regrowth (D) lacks evidence. A clinical pearl is biotin's interference with immunoassays. A decision framework involves checking supplement doses and lab timing per FDA warnings.

Question 2

1. Loperamide 4 mg once, then 2 mg after each loose stool (maximum 8 mg/day OTC) with oral rehydration (correct answer)
2. Senna 17.2 mg at bedtime to clear the intestines
3. Polyethylene glycol 17 g daily until diarrhea stops
4. Magnesium citrate 296 mL once for rapid symptom relief

Explanation: This question tests OTC antidiarrheal selection for traveler's diarrhea. The key patient-specific factors are acute, non-bloody diarrhea with hydration maintained, suitable for symptomatic relief. Loperamide with rehydration is most appropriate because it reduces stool frequency safely in uncomplicated cases. Senna (B) or laxatives (C, D) worsen diarrhea. Pharmacists should assess for dysentery signs. Guidelines from IDSA recommend loperamide for mild cases, adding antibiotics if severe.

Question 3

1. Advise discontinuing ginkgo biloba due to increased bleeding risk with warfarin (correct answer)
2. Advise doubling ginkgo biloba to 240 mg daily for faster benefit while on warfarin
3. Advise continuing ginkgo biloba and skipping warfarin doses if bruising occurs
4. Advise switching from warfarin to aspirin 81 mg daily to avoid interactions with ginkgo biloba

Explanation: This question tests management of supplement interactions with anticoagulants. The key patient-specific factor is ginkgo biloba's antiplatelet effects combined with warfarin, increasing bleeding risk. Advising discontinuation of ginkgo biloba is best because it prevents additive anticoagulation, maintaining stable INR and safety. Doubling ginkgo (B) worsens the risk, while skipping warfarin (C) disrupts therapeutic anticoagulation. Switching to aspirin (D) is suboptimal as it still interacts with ginkgo and may not suit atrial fibrillation management. A clinical pearl is to monitor INR frequently when starting/stopping supplements. A decision framework involves assessing bleeding risk using HAS-BLED scores and counseling on evidence-based alternatives.

Question 4

1. Recommend the potassium-based salt substitute because it improves blood pressure and is safe with spironolactone
2. Advise avoiding potassium-based salt substitutes due to hyperkalemia risk with spironolactone and elevated potassium (correct answer)
3. Recommend doubling spironolactone dose when using a salt substitute to maintain electrolyte balance
4. Recommend magnesium-based salt substitute as first-line treatment for heart failure

Explanation: This question tests OTC salt substitute safety in heart failure. The key patient-specific factors are spironolactone and elevated potassium, risking hyperkalemia with potassium-based substitutes. Advising avoidance is best because it prevents additive potassium retention and complications like arrhythmias. Recommending it (A) or doubling spironolactone (C) worsens risks; magnesium-based (D) lacks evidence. A clinical pearl is monitoring potassium weekly with changes. Guidelines recommend low-potassium diets in hyperkalemic patients.

Question 5

1. Continue current regimen because it is within the usual pediatric dosing range
2. Reduce to acetaminophen 10–15 mg/kg per dose every 4–6 hours as needed; for 22 kg, give 7–10 mL per dose (correct answer)
3. Switch to aspirin 325 mg every 4 hours as needed to avoid acetaminophen overuse
4. Increase to acetaminophen 20 mg/kg per dose every 4 hours for better fever control

Explanation: This question tests pediatric OTC dosing for antipyretics. The key patient-specific factor is the child's weight (22 kg) and overdosing with 15 mL (480 mg) every 4 hours, exceeding safe limits. Reducing to acetaminophen 10–15 mg/kg per dose every 4–6 hours (7–10 mL for 22 kg) is best because it provides effective fever control within safe parameters, preventing hepatotoxicity. Continuing the current regimen (A) risks overdose, while switching to aspirin (C) poses Reye's syndrome risk. Increasing the dose (D) worsens the overdose potential. For calculations: dose = 10–15 mg/kg; for 22 kg, 220–330 mg (7–10 mL of 160 mg/5 mL). Pharmacists should use weight-based dosing charts. Guidelines recommend maximum 75 mg/kg/day in children.

Question 6

1. Reinforce that acetaminophen is safe at any dose because it is not an NSAID
2. Identify duplicate acetaminophen therapy and counsel to limit total acetaminophen to a maximum of 3,000 mg/day from all sources (correct answer)
3. Switch to acetaminophen 1,500 mg every 6 hours to reduce the need for the cold product
4. Add ibuprofen 800 mg three times daily and continue current acetaminophen regimen

Explanation: This question tests recognition of acetaminophen overdose risk from multiple sources. The key patient-specific factor is liver disease increasing susceptibility to acetaminophen hepatotoxicity, with duplicate therapy identified. Identifying duplicate therapy and counseling to limit total acetaminophen to 3,000 mg/day is best because it prevents overdose while allowing safe use for headaches. Reinforcing unlimited safety (A) is a dangerous misconception, as doses over 4,000 mg/day risk toxicity. Switching to higher-dose acetaminophen (C) or adding ibuprofen (D) could exceed limits or add NSAID risks. A clinical pearl is to calculate total daily acetaminophen from all products. A decision framework includes using liver function tests to guide maximum doses in at-risk patients.

Question 7

1. Ibuprofen increasing bleeding risk when combined with warfarin (correct answer)
2. Omeprazole decreasing absorption of warfarin and lowering INR
3. Fish oil causing loss of warfarin efficacy by inducing hepatic enzymes
4. Acetaminophen decreasing warfarin effect and lowering INR

Explanation: This question evaluates the ability to identify clinically significant drug interactions with warfarin and OTC products. The key patient-specific factors are the patient's anticoagulation therapy (warfarin with therapeutic INR), history of gastrointestinal bleed, and occasional ibuprofen use. Ibuprofen increasing bleeding risk when combined with warfarin (A) is the most clinically significant interaction because NSAIDs like ibuprofen not only increase INR through platelet inhibition but also directly increase GI bleeding risk, especially concerning given her bleeding history. Omeprazole (B) does not decrease warfarin absorption or lower INR; it may actually slightly increase INR. Fish oil (C) does not induce hepatic enzymes or cause loss of warfarin efficacy; it may have mild antiplatelet effects. Acetaminophen (D) can actually increase INR with regular high doses, not decrease it. The clinical framework is that NSAIDs should be avoided in patients on warfarin, especially those with bleeding history, and acetaminophen is the preferred OTC analgesic.

Question 8

1. Terbinafine 1% cream applied once daily for 1 week (correct answer)
2. Hydrocortisone 1% cream applied twice daily for 2 weeks
3. Neomycin/polymyxin B/bacitracin ointment applied twice daily for 7 days
4. Zinc oxide paste applied after each shower until symptoms resolve

Explanation: This question tests OTC antifungal selection for tinea pedis in diabetic patients. The key patient-specific factor is type 2 diabetes with poor glycemic control, increasing infection risk and requiring effective, non-irritating therapy. Terbinafine 1% cream applied once daily for 1 week is most appropriate because it offers broad-spectrum antifungal activity with good penetration and safety in diabetics. Hydrocortisone (B) is suboptimal as it may mask symptoms without treating the fungus, while neomycin ointment (C) risks contact dermatitis and bacterial resistance. Zinc oxide (D) provides barrier protection but lacks antifungal efficacy. Pharmacists should inspect feet and recommend hygiene in diabetics. Guidelines from the American Diabetes Association emphasize prompt treatment to prevent complications like cellulitis.

Question 9

1. Add senna 8.6 mg, 2 tablets at bedtime as needed (correct answer)
2. Continue docusate only and increase calcium carbonate to improve bowel regularity
3. Start loperamide 2 mg after each loose stool to prevent worsening constipation
4. Use sodium phosphate enema daily for 7 days

Explanation: This question tests OTC management of opioid-induced constipation in elderly patients. The key patient-specific factor is chronic opioid use causing constipation, with inadequate response to docusate alone. Adding senna 8.6 mg, 2 tablets at bedtime as needed is most appropriate because it provides stimulant laxative effects to promote bowel motility safely in opioid-related constipation. Increasing calcium carbonate (B) is incorrect as it may worsen constipation, while loperamide (C) would exacerbate the issue by slowing motility. Sodium phosphate enema daily (D) is suboptimal due to risks of electrolyte imbalance and dehydration in the elderly. Pharmacists should evaluate bowel regimens in opioid users using tools like the Bristol Stool Scale. A decision framework includes starting with stool softeners, adding stimulants if needed, and monitoring for complications like fecal impaction.

Question 10

1. Magnesium citrate oral solution 296 mL once
2. Sodium phosphate enema as needed
3. Polyethylene glycol 17 g in water once daily as needed (correct answer)
4. Castor oil 30 mL once daily for 1 week

Explanation: This question tests safe laxative selection in advanced CKD. The key patient-specific factor is stage 4 CKD, where magnesium and phosphate laxatives risk accumulation and toxicity. Polyethylene glycol 17 g daily is most appropriate because it is osmotically active without electrolyte shifts, safe for renal impairment. Magnesium citrate (A) and sodium phosphate (B) can cause hypermagnesemia or hyperphosphatemia; castor oil (D) is harsh. Pharmacists should check eGFR before recommendations. Guidelines recommend PEG as first-line in CKD for its safety profile.

Question 11

1. Continue ibuprofen 400 mg three times daily and counsel to take with food to reduce stomach upset
2. Recommend naproxen 220 mg twice daily instead of ibuprofen because it is longer acting
3. Recommend acetaminophen 650 mg every 6 hours as needed (maximum 3,000 mg/day) and avoid routine NSAID use (correct answer)
4. Add aspirin 325 mg every 4–6 hours as needed and continue ibuprofen for better pain control

Explanation: This question tests patient-centered OTC medication management for osteoarthritis pain in patients with comorbidities. The key patient-specific factors are chronic kidney disease stage 3, hypertension treated with lisinopril and hydrochlorothiazide, and current ibuprofen use, which increase the risk of NSAID-induced renal injury. Recommending acetaminophen 650 mg every 6 hours as needed (maximum 3,000 mg/day) and avoiding routine NSAID use is the best choice because acetaminophen provides effective analgesia with a lower risk of nephrotoxicity and blood pressure elevation in this population. Continuing ibuprofen with food (A) is suboptimal as it does not mitigate the renal risks associated with chronic NSAID use in CKD, while switching to naproxen (B) introduces a similar long-acting NSAID that could further impair renal function. Adding aspirin (D) is incorrect because it adds another NSAID-like agent, increasing risks of gastrointestinal bleeding and renal harm without improving efficacy over monotherapy. A clinical pearl is to always evaluate renal function and concurrent medications when selecting OTC analgesics. Guidelines such as those from the American College of Rheumatology recommend acetaminophen as first-line for osteoarthritis in patients with CKD to prioritize safety.

Question 12

1. St. John's wort reducing clopidogrel effectiveness via enzyme induction (correct answer)
2. Calcium carbonate increasing clopidogrel absorption leading to bleeding
3. Omeprazole increasing clopidogrel activation leading to thrombosis
4. Calcium carbonate causing serotonin syndrome when combined with St. John's wort

Explanation: This question tests the identification of clinically significant drug-supplement interactions in patients on antiplatelet therapy. The key patient-specific factor is the use of St. John's wort with clopidogrel, which can lead to reduced antiplatelet efficacy. St. John's wort reducing clopidogrel effectiveness via enzyme induction is the most clinically significant interaction because it induces CYP3A4, potentially decreasing clopidogrel activation and increasing thrombotic risk post-stent. Calcium carbonate increasing clopidogrel absorption (B) is incorrect as it does not affect absorption and may actually decrease it if taken concurrently, while omeprazole increasing clopidogrel activation (C) is a misconception since PPIs like omeprazole inhibit CYP2C19, reducing activation. Calcium carbonate causing serotonin syndrome with St. John's wort (D) is suboptimal as this combination does not pose that risk, which is more associated with serotonergic drugs. Pharmacists should screen for herbal interactions using tools like natural product databases. A decision framework involves assessing interaction severity and monitoring needs, such as INR or platelet function, when supplements are added to critical therapies.

Question 13

1. Recommend continuing daily use because caffeine prevents medication-overuse headaches
2. Assess for medication-overuse headache and recommend limiting acute analgesic use; refer for evaluation of frequent headaches (correct answer)
3. Switch to a higher-dose aspirin product and continue daily use to prevent rebound
4. Add ibuprofen 800 mg three times daily to improve control and continue the combination product

Explanation: This question tests recognition of medication-overuse headache from OTC analgesics. The key patient-specific factor is frequent use of acetaminophen/aspirin/caffeine combination, potentially causing rebound headaches. Assessing for overuse and recommending limitation with referral is best because it addresses the cycle and prompts professional evaluation. Continuing or switching to higher doses (A, C) perpetuates overuse; adding ibuprofen (D) compounds risks. A clinical pearl is limiting acute treatments to <10 days/month. Guidelines from AHS recommend tracking usage and preventive strategies.

Question 14

1. Naproxen 500 mg twice daily for 5 days
2. Aspirin 650 mg every 4–6 hours as needed
3. Acetaminophen 650 mg every 6 hours as needed (maximum 3,000 mg/day) and refer for prescription flare therapy if needed (correct answer)
4. Ketorolac 10 mg every 6 hours as needed (OTC)

Explanation: This question tests OTC analgesia for gout flares in patients with GI history. The key patient-specific factor is prior peptic ulcer bleed, contraindicating NSAIDs. Acetaminophen with referral if needed is most appropriate because it provides safe pain relief without GI or uric acid effects. Naproxen (A) and aspirin (B) risk bleeding; ketorolac (D) is not OTC and shares risks. A clinical pearl is avoiding NSAIDs in high-GI-risk patients. Guidelines from ACR recommend colchicine or steroids for flares, using acetaminophen adjunctively.

Question 15

1. Recommend continuing diphenhydramine 50 mg nightly long-term because tolerance does not develop
2. Recommend adding doxylamine 25 mg nightly in addition to diphenhydramine for better effect
3. Recommend nonpharmacologic sleep hygiene and avoid sedating antihistamines with alcohol; consider lowering melatonin dose (e.g., 1–3 mg) if used (correct answer)
4. Recommend valerian root plus diphenhydramine and alcohol because the combination is synergistic and safe

Explanation: This question tests OTC insomnia management with alcohol use. The key patient-specific factors are high alcohol intake and sedating antihistamine causing grogginess, risking additive CNS depression. Recommending sleep hygiene and avoiding sedating agents with alcohol is best because it promotes safe, non-pharmacologic habits and considers melatonin dose reduction for efficacy. Continuing or adding antihistamines (A, B) increases risks; valerian with alcohol (D) is unsafe. Pharmacists should screen for substance use. Guidelines emphasize CBT-I and limiting sedatives in alcohol users.

Question 16

1. Pseudoephedrine 60 mg every 6 hours as needed
2. Oxymetazoline nasal spray 2–3 sprays per nostril twice daily for no more than 3 days (correct answer)
3. Diphenhydramine 50 mg every 6 hours as needed for congestion
4. Chlorpheniramine 4 mg every 4–6 hours as needed

Explanation: This question tests OTC decongestant selection in patients with benign prostatic hyperplasia. The key patient-specific factor is BPH on tamsulosin, where systemic alpha-agonists may worsen urinary symptoms. Oxymetazoline nasal spray 2–3 sprays per nostril twice daily for no more than 3 days is most appropriate because it provides topical decongestion without systemic effects impacting BPH. Pseudoephedrine (A) and phenylephrine (implied in D, but D is chlorpheniramine) are suboptimal as they can exacerbate urinary retention; diphenhydramine (C) adds anticholinergic burden. A misconception is that all decongestants are equivalent, but topical are safer in BPH. Pharmacists should limit topical use to avoid rebound. Guidelines recommend assessing prostate symptoms before systemic agents.

Question 17

1. Calcium carbonate can reduce iron absorption; separate iron and calcium-containing antacids by at least 2 hours (correct answer)
2. Ferrous sulfate increases calcium absorption leading to hypercalcemia
3. Calcium carbonate increases iron absorption leading to iron toxicity
4. Ferrous sulfate causes immediate ulcer healing when combined with calcium carbonate

Explanation: This question tests the clinical pharmacy concept of managing drug interactions between prescription medications and over-the-counter (OTC) products in patients with iron-deficiency anemia. The key patient-specific factor is the concurrent use of ferrous sulfate for anemia treatment and calcium carbonate for heartburn relief, alongside her low hemoglobin level indicating ongoing need for effective iron absorption. Choice A is the best answer because calcium carbonate can chelate with iron, reducing its absorption and potentially worsening anemia, so separating doses by at least 2 hours optimizes iron bioavailability and therapeutic efficacy. Choice B is incorrect as ferrous sulfate does not enhance calcium absorption to cause hypercalcemia, which is a misconception about bidirectional mineral interactions. Choices C and D are suboptimal; calcium does not increase iron absorption leading to toxicity, and ferrous sulfate combined with calcium carbonate does not promote ulcer healing but rather poses absorption issues. A transferable clinical pearl is to always assess for mineral interactions when recommending OTC antacids, prioritizing patient education on timing of doses to ensure safety and efficacy. Pharmacists should use resources like drug interaction checkers to guide recommendations for anemia management with concurrent GI therapies.

Question 18

1. Recommend continuing St. John's wort and separating it from sertraline by 2 hours
2. Recommend discontinuing St. John's wort due to risk of serotonin syndrome and drug interactions (correct answer)
3. Recommend adding diphenhydramine 25 mg nightly to counteract stimulation from St. John's wort
4. Recommend increasing sertraline dose while continuing St. John's wort for added benefit

Explanation: This question tests knowledge of herbal-drug interactions and appropriate counseling for psychiatric medications. The key patient-specific factor is concurrent use of sertraline (an SSRI) with St. John's wort, which has both serotonergic activity and CYP450 enzyme induction properties. Recommending discontinuation of St. John's wort (B) is correct because it poses dual risks: serotonin syndrome when combined with SSRIs and reduced sertraline levels through CYP3A4 induction. Separating doses by 2 hours (A) does not prevent these systemic interactions. Adding diphenhydramine (C) would not counteract stimulation and adds unnecessary anticholinergic burden. Increasing sertraline while continuing St. John's wort (D) is dangerous and could precipitate serotonin syndrome. The clinical pearl is that St. John's wort should be avoided with all antidepressants due to both pharmacodynamic (serotonin syndrome) and pharmacokinetic (enzyme induction) interactions.

Question 19

1. Continue current regimen because it is within the recommended pediatric dose range
2. Change to acetaminophen 10 mL every 6 hours and add ibuprofen 200 mg every 6 hours
3. Reduce to acetaminophen 7.5 mL every 6 hours as needed and avoid exceeding 5 doses in 24 hours (correct answer)
4. Stop acetaminophen and use aspirin 81 mg every 4 hours as needed for fever

Explanation: This question tests pediatric acetaminophen dosing and safety considerations. The key patient-specific factors are the child's weight (18 kg), age (5 years), and current dosing regimen of 10 mL every 4 hours around the clock. Reducing to 7.5 mL every 6 hours as needed (C) is correct because the current regimen provides 320 mg every 4 hours, which could exceed the maximum daily dose of 75 mg/kg/day (1,350 mg for this 18 kg child) if given 6 times daily. The correct dose is 10-15 mg/kg every 4-6 hours, which equals 180-270 mg per dose for this child, making 7.5 mL (240 mg) appropriate. Continuing the current regimen (A) risks exceeding daily maximum. Adding ibuprofen (B) is unnecessary if acetaminophen is dosed correctly. Aspirin (D) should be avoided in children due to Reye's syndrome risk. The clinical pearl is to always calculate pediatric doses based on weight (10-15 mg/kg/dose) and ensure the total daily dose doesn't exceed 75 mg/kg/day or 5 doses in 24 hours.

Question 20

1. Recommend continuing both products and adding naproxen 220 mg twice daily for additional pain relief
2. Assess total daily acetaminophen from all products and recommend avoiding duplicate acetaminophen to reduce hepatotoxicity risk (correct answer)
3. Recommend switching to acetaminophen 650 mg extended-release every 4 hours to reduce liver risk
4. Recommend adding an OTC niacin supplement to support liver function while continuing current products

Explanation: This question evaluates recognition of duplicate acetaminophen exposure from combination products. The key patient-specific factors are nonalcoholic fatty liver disease, regular alcohol consumption (2-3 beers nightly), and concurrent use of both a combination cold product and standalone acetaminophen. Assessing total daily acetaminophen intake (B) is correct because many OTC cold products contain acetaminophen, and taking additional acetaminophen creates risk of exceeding the 4 g/day maximum (or lower in hepatic impairment). Adding naproxen (A) ignores the acetaminophen duplication issue. Extended-release acetaminophen (C) doesn't address the fundamental problem of duplicate dosing. Niacin supplementation (D) has no role in preventing acetaminophen hepatotoxicity. The clinical framework is to always check all OTC combination products for hidden acetaminophen, especially in patients with liver disease or alcohol use, and limit total daily dose to 2-3 g in these patients.